Poseida Therapeutics to Present at BofA Securities 2023 Health Care Conference
Get Alerts PSTX Hot Sheet
Join SI Premium – FREE
A live webcast of the presentation will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. The Company has formed global strategic collaborations with Roche and Takeda to unlock the promise of cell and gene therapies for patients. Learn more at www.poseida.com and connect with Poseida on Twitter and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-bofa-securities-2023-health-care-conference-301811413.html
SOURCE Poseida Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SCHLOTZSKY'S DELI BRINGS A TEXAS-SIZED TAKE TO A PHILLY CLASSIC WITH NEW PHILLY CHEESESTEAK LINEUP
- MGM RESORTS & BETMGM COMMIT $300,000 TO RESPONSIBLE GAMING RESEARCH & PARTNERSHIPS
- Encryption Consulting Launches CertSecure Manager MCP Server, Enabling AI-Powered Certificate Lifecycle Management Through Agentic AI
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share